Long Term Safety Assessment of SER120 in Patients With Nocturia

Completed · Phase 3

Conditions studied: Nocturia

In brief

The hypothesis of this study is that SER120 is safe and well tolerated for use in nocturic patients.

Key facts

Study ID

NCT00981682

Run by

Serenity Pharmaceuticals, Inc.

People needed

376

Starts

2009-08-01

Expected to finish

2011-08-01

Last updated by the study team

2021-01-20

Who can join

Age: 50 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients completed SPC-SER120-DB1-200901 and SPC-SER120-DB2-200902 studies
• Willing to provide consent for the study

You may not qualify if…

• Incontinence
• Diabetes Insipidus, Diabetes Mellitus
• CHF
• Renal Insufficiency
• Significant medical history which make participation unacceptable

Where it is running

• Stephen M. Auerbach, MD — Newport Beach, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.